According to filings with the U.S. Securities and Exchange Commission, Santa Ana Bio is raising up to $125,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Peter Emtage played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Santa Ana Bio
Santa Ana Bio is a precision immunology company leveraging multi-omics platforms and antibody engineering to deliver targeted therapies to patients with autoimmune and inflammatory diseases. At Santa Ana Bio we are developing novel therapeutics including monoclonals, bi-specifics and antibody drug conjugates to treat patients with serious immune mediated diseases.

To learn more about Santa Ana Bio, visit http://www.santaanabio.com/
Company Linkedin Page: https://www.linkedin.com/company/santaanabio/

Contact:
Peter Emtage, Chief Executive Officer
858-705-2660
https://www.linkedin.com/in/peter-emtage-ph-d-5034bb3/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.